A Prospective Multicenter Randomized Trial to Assess the Safety and Effectiveness of EXCEL-II Sirolimus Eluting Stent vs. EXCEL Sirolimus Eluting Stent for the Treatment of Patients With de Novo Coronary Artery Lesions .( CREDIT II Trial )

Trial Profile

A Prospective Multicenter Randomized Trial to Assess the Safety and Effectiveness of EXCEL-II Sirolimus Eluting Stent vs. EXCEL Sirolimus Eluting Stent for the Treatment of Patients With de Novo Coronary Artery Lesions .( CREDIT II Trial )

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms CREDIT-II
  • Sponsors JW Medical Systems
  • Most Recent Events

    • 01 Mar 2017 Results of a pooled analysis assessing objective performance criteria in patients from two clinical studies (CREDIT-II and CREDIT-III; n=833), published in the Catheterization and Cardiovascular Interventions
    • 11 Mar 2015 Status changed from recruiting to active, no longer recruiting, as reported in a Biosensors International Group media release.
    • 12 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top